U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H17F2N5O3S
Molecular Weight 409.41
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VERUBECESTAT

SMILES

CN1C(N)=N[C@@](C)(CS1(=O)=O)C2=CC(NC(=O)C3=CC=C(F)C=N3)=CC=C2F

InChI

InChIKey=YHYKUSGACIYRML-KRWDZBQOSA-N
InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1

HIDE SMILES / InChI
Verubecestat (MK 8931) is a potentially first-in-class, potent β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor being developed by Merck. Verubecestat (MK-8931) is a selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of Aβ40, Aβ42, and sAPPβ (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys. Verubecestat was under investigation for the treatment of Alzheimer's disease, prodromal Alzheimer's disease, and amnestic mild cognitive impairment. In November 2013, Merck began the APECS trial in 1,500 participants with prodromal AD, aka mild cognitive impairment due to AD (aMCI). These patients have measurable cognitive deficits and a positive PET scan with the newly FDA-approved amyloid tracer flutemetamol, but are not functionally impaired. APECS compared 12 and 40 mg once-daily doses to placebo; treatment was to last for two years. APECS usef change from baseline on the Clinical Dementia Rating Sum of Boxes (CDR-SB), a continuous measure, as its primary outcome. Secondary outcomes evaluated a range of newer measures, including a cognitive composite, CSF tau, brain imaging of hippocampal volume and amyloid load, and others. This trial was being conducted in more than 90 locations worldwide; it completed enrollment in November 2016 and was expected to complete data collection for its primary outcome in 2019. In February 2018, APECS was discontinued and Merck no longer listed verubecestat in its research pipeline. APECS participants on 40 mg verubecestat scored worse than the placebo group on the CDR-SB and ADAS-Cog13 starting at 13 weeks. The effect was small and did not progress over time. The 12 mg treatment group also performed slightly worse than controls, with the difference reaching significance at scattered time points.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.8 nM [Ki]
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

12, 40, or 60 mg/day of Verubecestat (MK 8931) given as once-daily tablets to placebo in people with mild to moderate AD.
Route of Administration: Oral
Name Type Language
VERUBECESTAT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
VERUBECESTAT [USAN]
Common Name English
VERUBECESTAT [JAN]
Common Name English
verubecestat [INN]
Common Name English
SCH-900931
Code English
SCH900931
Code English
2-PYRIDINECARBOXAMIDE, N-(3-((5R)-3-AMINO-5,6-DIHYDRO-2,5-DIMETHYL-1,1-DIOXIDO-2H-1,2,4-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5-FLUORO-
Systematic Name English
Verubecestat [WHO-DD]
Common Name English
SCH 900931
Code English
MK-8931
Code English
Classification Tree Code System Code
NCI_THESAURUS C471
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
NCI_THESAURUS C1509
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C152868
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
EVMPD
SUB185177
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
CAS
1286770-55-5
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
SMS_ID
100000170947
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
FDA UNII
J1I0P6WT7T
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
WIKIPEDIA
Verubecestat
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID30102062
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
PUBCHEM
51352361
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL3301601
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
INN
10028
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
CAS
1613380-81-6
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
SUPERSEDED
USAN
BC-75
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY
DRUG BANK
DB12285
Created by admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
PRIMARY